Renal cell carcinoma epidemiology and demographics

Jump to navigation Jump to search

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Yazan Daaboul; Serge Korjian; Rim Halaby, M.D. [2]

Renal cell carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal cell carcinoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal cell carcinoma epidemiology and demographics On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal cell carcinoma epidemiology and demographics

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal cell carcinoma epidemiology and demographics

CDC on Renal cell carcinoma epidemiology and demographics

Renal cell carcinoma epidemiology and demographics in the news

Blogs on Renal cell carcinoma epidemiology and demographics

Directions to Hospitals Treating Renal cell carcinoma

Risk calculators and risk factors for Renal cell carcinoma epidemiology and demographics

Overview

Renal cell carcinoma is considered the 7th most common cancer in men and 9th most common cancer in women, accounting for approximately 2-3% of malignant tumors in adults. Men are twice more likely to be affected than women with a mean age of presentation at 60 years. Most renal cell carcinomas develop sporadically, while only a small number of cases are of genetic diseases. Clear cell carcinomas are the most common renal cell carcinomas and collecting-duct carcinomas are the least common. Renal cell carcinomas are mostly found incidentally during radiological abdominal work-up.

Epidemiology

Prevalence

  • Renal cell carcinoma accounts for approximately 2-3% of all malignant tumors in the adult population.[1] Most cases of renal cell carcinoma are sporadic; whereas only approximately 2-3% of all cases are familial, most of which have an autosomal-dominant pattern of inheritance.[1]
  • In the United States, the age-adjusted prevalence of kidney cancer is 85.9 per 100,000 in 2011.[2]

Incidence

  • The delay-adjusted incidence of kidney cancer in 2011 was estimated to be 15.88 per 100,000 persons in the United States.[2]
  • In 2011, the age-adjusted incidence of kidney cancer was 15.28 per 100,000 persons in the United States.[2]

Age

  • The median age of presentation is typically 60 years.[1]
  • While the overall age-adjusted incidence of kidney cancer in the United States between 2007 and 2011 is 15.5 per 100,000, the age-adjusted incidence of kidney cancer by age category is:[2]
    • Under 65 years: 8.3 per 100,000
    • 65 and over: 65 per 100,000

Gender

  • Renal cell carcinomas is considered the 7th most common cancer in men and the 9th most common cancer in women.
  • The male to female ratio is approximately 2 to 1.[1] The ratio increases dramatically increases in sporadic cases of papillary renal cell carcinomas, reaching a 5 to 1 ratio.[3]
  • In the United States, the age-adjusted prevalence of kidney cancer by gender in 2011 is:[2]
    • In males: 113.2 per 100,000
    • In females: 63.3 per 100,000
  • In the United States, the delay-adjusted incidence of kidney cancer by gender in 2011 is:[2]
    • In males: 21.84 per 100,000 persons
    • In females: 10.81 per 100,000 persons
  • In the United States, the age-adjusted incidence of kidney cancer by gender on 2011 is:[2]
    • In males: 21.02 per 100,000 persons
    • In females: 10.4 per 100,000 persons
  • Shown below is an image depicting the delay-adjusted incidence and observed incidence of kidney cancer by gender and race in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[2]

Delay-adjusted incidence and observed incidence of kidney cancer by gender and race in the United States between 1975 and 2011

Race

  • Shown below is a table depicting the age-adjusted prevalence of kidney cancer by race in 2011 in the United States.[2]
All Races White Black Asian/Pacific Islander Hispanic
Age-adjusted prevalence 85.9 per 100,000 90.8 per 100,000 91.3 per 100,000 46.7 per 100,000 86.7 per 100,000
  • Shown below is an image depicting the incidence of kidney cancer by race in the United States between 1975 and 2011.[2]

Incidence of kidney cancer by race in the United States between 1975 and 2011

API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native

Percent Distribution of Renal cell Carcinoma by Histology

More than 70% of renal cell carcinomas are clear cell carcinomas. Papillary carcinomas are the second most common renal cell carcinomas. The least common types of renal cell carcinomas are collecting-duct renal cell carcinomas, accounting for less than 1% of all cases.[3]

References

  1. 1.0 1.1 1.2 1.3 Rini BI, Campbell SC, Escudier B (2009). "Renal cell carcinoma". Lancet. 373 (9669): 1119–32. doi:10.1016/S0140-6736(09)60229-4. PMID 19269025.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
  3. 3.0 3.1 Cohen HT, McGovern FJ (2005). "Renal-cell carcinoma". N Engl J Med. 353 (23): 2477–90. doi:10.1056/NEJMra043172. PMID 16339096.